Therapeutic interventions, such as immune checkpoint blockade targeting molecules like PD-1/PD-L1 and CTLA-4, aim to overcome this challenge; they are not specific for HPV antigens, and if successful, they can be efficient in the majority of cervical cancer cases, regardless of the associated HPV type (9). The gene discussed is CD274; the disease is cervical carcinoma.